Latest Blood disorders Stories
ROCKVILLE, Md., June 13, 2012 /PRNewswire/ -- This week's announcement by ABC News' Robin Roberts that she has been diagnosed with MDS (myelodysplastic syndrome) has drawn national attention to this bone marrow failure disorder. Since 1983, the Aplastic Anemia & MDS International Foundation (www.AAMDS.org) has provided education and support to patients with MDS. MDS is a group of rare disorders affecting the bone marrow. People with MDS have an abnormal number of red and white...
-People newly diagnosed with chronic leukemia must often wait to learn if they have a faster- or slower-progressing form of the disease. -This study identified a molecular marker that quickly helps to distinguish which form a patients has. -The findings could enable patients with aggressive disease to start treatment sooner. Researchers have identified a prognostic marker in the most common form of chronic leukemia that can help to distinguish which patients should start treatment...
KING OF PRUSSIA, Pa., June 8, 2012 /PRNewswire/ -- CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The Orphan Drug Designation is granted for the treatment and prophylaxis of bleeding episodes in patients with congenital factor IX deficiency (hemophilia B). The designation includes routine...
TOKYO and SAN DIEGO, June 4, 2012 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation today announced the initiation of a Phase 2b open-label clinical trial of quizartinib as monotherapy in patients with relapsed and refractory acute myeloid leukemia (AML) with FLT3-ITD mutations. The trial will enroll approximately 64 adult patients (the estimated enroll of the protocol) in the United States and Europe to evaluate two oral doses of...
About 75 percent of children with leukemia who take chemotherapy face life-threatening heart problems as they age, but an international study led by a University of Rochester Medical Center investigator shows that giving a cardio-protective drug during cancer treatment may prevent the damage. Researchers and physicians will debate how to make young cancer patients and their families aware of the risks of heart damage, and the best ways to manage the risks, in a special session today at the...
CHICAGO, June 4, 2012 /PRNewswire/ -- Pharmacyclics, Inc (Nasdaq: PCYC) announced today updated results from three trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). "This meeting at ASCO has been a continued affirmation of the promising activity and clinical benefit of ibrutinib in CLL. It will be exciting to move this toward definitive Phase III study...
SOUTH SAN FRANCISCO, Calif. and HOUSTON, June 4, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) and The University of Texas MD Anderson Cancer Center today announced a non-exclusive research alliance for pre-clinical and clinical research to continue to understand the role that novel experimental therapies, including Onyx's carfilzomib and oprozomib, can play in the potential treatment of multiple myeloma and lymphoma. The term of the agreement extends for two years....
SEATTLE, June 4, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), announced today that it has completed its acquisition gaining world-wide rights to S*BIO Pte Ltd.'s ("S*BIO") pacritinib. Pacritinib is a highly selective oral JAK2 (Janus Associated Kinase 2) inhibitor that demonstrated encouraging clinical activity in phase 1 and 2 clinical studies of patients with primary myelofibrosis ("MF") and MF secondary to other myeloproliferative neoplasms...
In a heartwarming meeting, Vincent Valenti, 35, of White Plains, NY, finally had the chance to personally thank Stefan Hindl, 32, from Germany for his life-saving bone marrow donation at North Shore University Hospital. Woodbury, NY (PRWEB) June 01, 2012 Mr. Valenti, the father of 16-month-old twin boys, was able to survive his ongoing battle with Acute Lymphoblastic Leukemia (ALL), after receiving the transplant in September 2009 at [North Shore University Hospital (NSUH). The two men...
NORTH WALES, Pa., June 1, 2012 /PRNewswire/ -- Teva Oncology presented two secondary analyses today featuring omacetaxine mepesuccinate, an investigational, first-in-class cephalotaxine that functions as a protein synthesis inhibitor at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago. These analyses were derived from data that was submitted to the US Food and Drug Administration as part of a new drug application (NDA) and was recently accepted for...
